摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-(1-氨基乙基)苯酚 | 518060-42-9

中文名称
(R)-3-(1-氨基乙基)苯酚
中文别名
——
英文名称
(R)-3-(1-aminoethyl)phenol
英文别名
3-[(1R)-1-aminoethyl]phenol
(R)-3-(1-氨基乙基)苯酚化学式
CAS
518060-42-9
化学式
C8H11NO
mdl
MFCD04972530
分子量
137.181
InChiKey
WFRNDUQAIZJRPZ-ZCFIWIBFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    266.3±15.0 °C(Predicted)
  • 密度:
    1.096±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922299090

SDS

SDS:deb26ac8650490d23e983b70d9819de8
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    General Strategy for Large-Scale Synthesis of (+)-Rivastigmine and (+)-NPS R-568
    摘要:
    An economically viable strategy for the total synthesis of (+)-rivastigmine and (+)-NPS R-568 has been reported. The strategy involves regioselective hydrogenation of diastereomerically pure bis amine to realize the desired alpha-methyl chiral substituted benzyl amine. The route is economical, scalable, and versatile enough to be adapted to similar classes of compounds.
    DOI:
    10.1080/00397911.2010.527425
  • 作为产物:
    描述:
    (R)-(+)-1-(3-甲氧基苯基)乙胺氢溴酸 为溶剂, 以to give (R)-1-(3-hydroxyphenyl)ethylamine的产率得到(R)-3-(1-氨基乙基)苯酚
    参考文献:
    名称:
    SALTY TASTE ENHANCER
    摘要:
    本发明提供了一种具有增强咸味活性的化合物,以及含有该化合物的增强咸味剂等。本发明涉及一种用于食品或饮料的增强咸味剂,其包含下式所示的化合物:其中每个符号如规范中所定义,或其可食用盐。
    公开号:
    US20140004243A1
点击查看最新优质反应信息

文献信息

  • [EN] BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS BENZOLACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2017068412A1
    公开(公告)日:2017-04-27
    The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
    该发明提供了一个化合物,其化学式为(0):或其药学上可接受的盐、N-氧化物或互变异构体。这些化合物是ERK 1/2激酶的抑制剂,并将在治疗ERKl/2介导的疾病中发挥作用。因此,这些化合物在治疗中特别是在癌症治疗中是有用的。
  • [EN] COMPOUNDS WITH NEURAL PROTECTIVE EFFECT, AND PREPARATION AND USE THEREOF<br/>[FR] COMPOSÉS PROTÉGEANT LES NEURONES, PRÉPARATION ET UTILISATION DE CES DERNIERS
    申请人:GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD
    公开号:WO2015109935A1
    公开(公告)日:2015-07-30
    The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    该发明通常涉及具有神经保护作用的化合物(I)的公式,以及其制备和用途。这些化合物具有多种机制或功能,例如,抑制单胺氧化酶和胆碱酯酶,清除自由基,并保护神经细胞等细胞。这些化合物可用于制造细胞保护药物,用于预防和/或治疗与单胺氧化酶、胆碱酯酶和自由基相关的疾病,例如,阿尔茨海默病、帕森病和中风等神经退行性疾病,以及与心脏病、心肌缺血、糖尿病和其他心血管和脑血管疾病相关的自由基相关疾病。
  • COMPOUNDS WITH NEURAL PROTECTIVE EFFECT, AND PREPARATION AND USE THEREOF
    申请人:GUANGZHOU MAGPIE PHARMACEUTICAL CO., LTD
    公开号:US20160326099A1
    公开(公告)日:2016-11-10
    The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    该发明通常涉及具有神经保护作用的化合物(I)的公式,以及其制备和用途。这些化合物具有多种机制或功能,例如,抑制单胺氧化酶和胆碱酯酶,清除自由基,并保护神经细胞等细胞。这些化合物可用于制造细胞保护药物,用于预防和/或治疗与单胺氧化酶、胆碱酯酶和自由基相关的疾病,例如,阿尔茨海默病、帕森病和中风等神经退行性疾病,以及与自由基相关的疾病,如心脏病、心肌缺血、糖尿病和其他心血管和脑血管疾病。
  • [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE<br/>[FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
    申请人:SENTINEL ONCOLOGY LTD
    公开号:WO2010136755A1
    公开(公告)日:2010-12-02
    The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O ); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.
    该发明提供了式(1)的化合物或其盐或互变异构体;其中X1为N或N+(O-);X2为N或CH;Q为C1-3烷基基团;R1从氢、C1-4烃基和羟基-C2-4烃基中选择;R2、R3和R4相同或不同,每个从氢、和甲基中选择;Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环,或者是一个环;Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式(1)的化合物是p70S6激酶的抑制剂,可用于治疗增殖性疾病。
  • [EN] RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA RHO KINASE ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    申请人:CHDI FOUNDATION INC
    公开号:WO2020264405A1
    公开(公告)日:2020-12-30
    Provided herein are certain inhibitors of ROCK (rho-kinases or rho-associated kinases), which are useful as medicament, for the treatment Huntington's disease in particular.
    本文提供了一些ROCK(rho激酶或rho相关激酶)的抑制剂,这些抑制剂在特定情况下可用作药物,用于治疗亨廷顿病。
查看更多